

March 5, 2019



## **Propanc Biopharma to Present at the 31st Annual ROTH Conference March 17 – 19, 2019**

MELBOURNE, Australia--(BUSINESS WIRE)-- [Propanc Biopharma, Inc.](#) (OTCQB:PPCB) ("Propanc"), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today that its Chief Executive Officer, James Nathanielsz, has been invited to present at the 31<sup>st</sup> Annual ROTH Conference being held on March 17 – 19, 2019 at the Ritz Carlton, Laguna Niguel located in Orange County, California.

The conference will feature presentations from public and private companies across a variety of industry sectors and is one of the largest of its kind in the US. Last year, the ROTH Conference hosted close to 550 participating companies and more than 4,700 attendees, including institutional investors, analysts, family offices and high net worth investors.

Mr. Nathanielsz is scheduled to present in one-on-one meetings with institutional analysts and investors throughout the day on March 19. He will be discussing Propanc's plans for advancing its lead product, PRP, towards human trials this year.

ROTH will host a pre-recorded webcast of Propanc's presentation, which will be available on the conference website at <http://wsw.com/webcast/roth33/ppcb/> beginning on March 11.

Investors and potential partners attending the conference who wish to meet with Propanc's management can contact their ROTH representative. For those not planning to attend the conference, please contact Lisa DeScenza to set up a call with Mr. Nathanielsz to learn more about Propanc.

### **About Propanc Biopharma, Inc.**

Propanc Biopharma, Inc. (the "Company") is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers. For more information, please visit [www.propanc.com](http://www.propanc.com).

### **Propanc Biopharma's Pancreatic Enzyme Therapy Platform**

Propanc Biopharma's novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body's primary defense against cancer.

To view the Company's "Mechanism of Action" video on anti-cancer product candidate, PRP, please click on the following link: <http://www.propanc.com/news-media/video>.

## Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are “forward-looking statements,” which may often, but not always, be identified by the use of such words as “may,” “might,” “will,” “will likely result,” “would,” “should,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “continue,” “target” or the negative of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. These factors include uncertainties as to the Company’s ability to continue as a going concern absent new debt or equity financings; the Company’s current reliance on substantial debt financing that it is unable to repay in cash; the Company’s ability to successfully remediate material weaknesses in its internal controls; the Company’s ability to reach research and development milestones as planned and within proposed budgets; the Company’s ability to control costs; the Company’s ability to obtain adequate new financing on reasonable terms; the Company’s ability to successfully develop PRP, its lead product candidate; the Company’s ability to obtain and maintain patent protection; the Company’s ability to recruit employees and directors with accounting and finance expertise; the Company’s dependence on third parties for services; the Company’s dependence on key executives; the impact of government regulations, including FDA regulations; the impact of any future litigation; the availability of capital; changes in economic conditions, competition; and other risks, including, but not limited to, those described in the Company’s Registration Statement on Form S-1, filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 25, 2019, and in the Company’s other filings and submissions with the SEC. These forward-looking statements speak only as of the date hereof and the Company disclaims any obligations to update these statements except as may be required by law.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20190305005481/en/>

### Investor Relations and Media:

Lisa DeScenza

Assistant Vice President, Integrated Communications

(978) 395-5970

[ldescenza@lavoiehealthscience.com](mailto:ldescenza@lavoiehealthscience.com)

Anthony Karamourtopoulos

Account Executive

(617) 792-3540

[akara@lavoiehealthscience.com](mailto:akara@lavoiehealthscience.com)

Source: Propanc Biopharma, Inc.